NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01667263,The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia,https://clinicaltrials.gov/study/NCT01667263,,COMPLETED,"Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.",NO,Autoimmune Thrombocytopenia,DRUG: All-trans retinoic acid|DRUG: Danazol,"the sustained platelet response at the 12-month follow-up, The number of participants (responders) with platelet count \>=30x10\^9/L and at least a 2-fold increase in the baseline count (PR) or a platelet count \>=100x10\^9/L (CR) and the absence of bleeding, without rescue medication at 12-month follow-up., From the start of study treatment (Day 1) up to the end of Month 12","overall response, The number of participants with platelet count \>=30×10\^9/L at least once and at least a doubling of the baseline platelet count without the administration of any other platelet increasing therapy, From the start of study treatment (Day 1) up to the end of Month 12|primary response rate at 4 weeks, The number of participants with platelet count \>=30×10\^9/L and at least a doubling of the baseline platelet count without the administration of any other platelet increasing therapy at week 4 of treatment, From the start of study treatment (Day 1) up to week 4 of treatment|primary response rate at 8 weeks, The number of participants with platelet count \>=30×10\^9/L and at least a doubling of the baseline platelet count without the administration of any other platelet increasing therapy at week 8 of treatment, From the start of study treatment (Day 1) up to week 8 of treatment|time to response, Time to response was defined as the time from starting treatment to the time to achieve the response., From the start of study treatment (Day 1) up to the end of month 12|duration of response, Duration of response was measured from the achievement of response to the loss of response., From the start of study treatment (Day 1) up to the end of month 12|reduction in bleeding symptoms, Changes of bleeding after treatment. Bleeding was defined in accordance with the WHO bleeding scale (0, no bleeding; 1, petechiae; 2, mild blood loss; 3, gross blood loss; and 4, debilitating blood loss)., From the start of study treatment (Day 1) up to the end of month 12|safety, All patients were assessed for safety every week during the first 8 weeks of treatment, and at 2-week intervals thereafter. Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, From the start of study treatment (Day 1) up to the end of follow-up",,Peking University People's Hospital,"Beijing Municipal Science & Technology Commission|Beijing Hospital|Qilu Hospital of Shandong University|Navy General Hospital, Beijing|Beijing Tongren Hospital",ALL,"ADULT, OLDER_ADULT",PHASE2,130,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,U1111-1132-6877|Z111107058811024,2012-06-01,2016-07-01,2017-02-01,2012-08-17,,2017-09-07,"Beijing Hospital, Ministry of Health, Beijing, Beijing, 100044, China|Peking University People's Hospital, Peking University Insititute of Hematology, Beijing, Beijing, 100044, China|Beijing Tongren Hospital, Beijing, Beijing, China|PLA Navy General Hospital, Beijing, Beijing, China|Qilu Hospital, Shandong University, Jinan, Shandong, China",
